Business
InMed to Present at 30th Annual ROTH Capital Conference
InMed to Present at 30th Annual ROTH Capital Conference Canada NewsWire VANCOUVE...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed to Present at 30th Annual ROTH Capital Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, March 12, 2018\n\n\n\nVANCOUVER, March 12, 2018 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (CSE: IN; OTCQB: IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, announced today that Eric A. Adams, CEO & President, will be presenting to U.S. institutional investors at the 30th Annual ROTH Conference, which is being held March 11-14, 2018, at the Ritz Carlton, Laguna Niguel, California.  InMed's presentation at the conference is currently scheduled for Tuesday, March 13th, at 3:30 PM, PST.\n\n\"The ROTH Conference is one of the largest emerging growth and healthcare-focused events in the United States, and it does a wonderful job introducing small and mid-cap companies to investors who are focused on companies with high-growth potential,\" commented Mr. Adams. \"InMed Pharmaceuticals is honored to have been asked to present to this assembly of investors who represent significant resources in the healthcare space.\"\n\nAbout InMed:InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.\n\nAbout ROTH Capital Conference:ROTH Capital Partners 30th Annual Conference is one of the largest of its kind in the U.S. Following the success of previous years' events, the ROTH Conference, with close to 500 participating co...